查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856578

被忽視的熱帶疾病診斷市場：按技術、疾病類型、最終用戶、應用和樣本類型分類－2025-2032年全球預測

Neglected Tropical Diseases Diagnosis Market by Technology, Disease Type, End User, Application, Sample Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

被忽視的熱帶疾病診斷市場預計到 2032 年將成長至 112.7 億美元，複合年成長率為 6.04%。

關鍵市場統計數據
基準年 2024 70.4億美元
預計年份：2025年 74.7億美元
預測年份 2032 112.7億美元
複合年成長率 (%) 6.04%

本文旨在介紹被忽視的熱帶疾病（NTL）診斷在全球衛生優先事項和商業現實中的地位，從而指南策略決策。

被忽視的熱帶疾病（NTDs）在許多中低收入國家仍然是持續存在的公共衛生挑戰，並對衛生系統和發展夥伴提出了複雜的診斷要求。 NTDs的診斷策略必須在滿足敏感性和特異性需求的同時，兼顧基礎設施、人力和供應鏈韌性方面的限制。隨著全球衛生相關人員致力於疾病的全面控制和消除，診斷發揮核心作用，它既是臨床治療的推動因素，也是為計畫決策提供資訊的監測工具。

分析了影響不同衛生系統中被忽視的熱帶疾病診斷的關鍵技術、監管、規劃和採購轉變。

被忽視的熱帶疾病（NTD）診斷正經歷多重變革，這些變革受到技術、規劃和政策等多面向因素的驅動。分子生物學、小型化設備和數位連接的創新降低了技術門檻，使得在分散的醫療環境中也能使用更靈敏的檢測方法。同時，人們越來越重視綜合診斷，以支持多病種篩檢和監測，這反映了提高衛生系統效率和最佳化資源配置的趨勢。

檢驗了不斷變化的貿易政策和關稅壓力如何改變診斷性籌資策略、供應鏈韌性以及影響專案永續性的採購權衡。

近期主要市場貿易政策和關稅結構的變化，為診斷供應鏈帶來了新的成本考量，影響了試劑、耗材和診斷硬體的籌資策略。進口關稅和海關政策的變化不僅會影響到岸成本，還會影響採購週期的彈性。關稅法規與區域製造能力之間的相互作用，是決定供應商在何處進行本地化生產或庫存管理的關鍵因素。

基於全面細分的洞察，將診斷技術、疾病特定需求、最終用戶場景、應用和樣本類型與採用優先順序聯繫起來。

對技術、疾病類型、最終用戶、應用和樣本類型等細分領域的深入理解，能夠清楚地揭示創新和推廣路徑。在技​​術領域，免疫測量（包括化學冷光檢測和酵素結合免疫吸附試驗）在血清學監測和確診檢測中仍然發揮著重要作用，而顯微鏡技術（包括螢光和光學顯微鏡）在許多情況下仍然是低成本診斷的基礎手段。分子診斷技術（包括聚合酵素鏈鎖反應和等溫擴增檢測）對低寄生蟲負荷感染疾病具有高靈敏度，並在確診過程中扮演越來越重要的角色。能夠同時檢測抗原和抗體的快速診斷測試，為社區篩檢和即時檢測決策提供了所需的便利性和速度。

影響美洲、歐洲、中東和非洲以及亞太地區診斷服務取得和實施選擇的專案和營運促進因素

區域動態持續影響專案優先事項、診斷手段的可及性和產品推廣路徑。在美洲，城鄉差距和地方性流行區域使得將無核化熱帶病（NTD）診斷納入更廣泛的基層醫療服務成為必要，同時在三級醫療中心配備實驗室確診能力，並利用快速篩檢工具開展遠距推廣。跨境協調和區域公共衛生舉措影響採購協調和數據共用實踐，從而支持有針對性的消除項目。

本文旨在探討被忽視的熱帶疾病診斷領域的競爭格局、合作夥伴關係和產品差異化策略。

被忽視的熱帶疾病（NTD）診斷領域的競爭生態系統由成熟的診斷試劑生產商、專注於特定領域的專業開發商、學術實驗室以及支持驗證和臨床評估的合約研發機構組成。現有企業正在調整其產品組合，以滿足對整合檢測解決方案和數位化連接的需求，而規模較小的創新企業則傾向於專注於顛覆性平台，例如簡易的等溫擴增方法、新型抗原檢測化學方法以及專為現場部署而設計的無需儀器的讀數設備。

為製造商、資助者和專案規劃者提供切實可行的建議，以使診斷創新與現場部署實際情況和專案永續性適應。

產業領導者應採取務實的多管齊下策略，使創新與實際營運相契合。首先，應優先發展那些注重穩健性、易用性以及最大限度減少對複雜低溫運輸和先進基礎設施依賴的研發路徑，從而拓寬診斷技術有效部署的環境範圍。其次，應投資進行檢驗研究，以證明其在專案實施條件下以及在相關樣本類型中的性能，從而增強採購機構和第一線醫護人員的信心。

對混合方法研究途徑進行了清晰的解釋，該方法結合了相關人員訪談、文獻綜述和比較分析，為所提出的見解提供了理論基礎。

本報告整合了一手和二手研究資料，結合相關人員訪談、產品性能文獻、監管指導文件和實地檢驗研究，以三角驗證的方式得出結論。一手資料包括對診斷試劑開發人員、實驗室主任、地方性流行病臨床醫生、採購專業人員和公共衛生專案經理的結構化訪談，從定性觀點分析了可用性、供應鏈考量和推廣障礙。二級資訊來源包括關於診斷性能的同行評審文獻、已發布的監管標準以及與被忽視的熱帶疾病（NTD）計畫實施相關的國際衛生機構技術指南。

策略結論強調，務實創新、夥伴關係和採購協調是改善診斷和實現公共衛生持續成長的途徑。

診斷是防治被忽視的熱帶疾病的關鍵，它既有助於個別患者的治療，也有助於實現人群層面的計畫目標。技術進步、採購慣例的改變以及對監測的日益重視，共同為彌合數十年來一直存在的診斷差距提供了機會。要充分發揮這項潛力，需要研發人員、資助者、專案執行者和監管機構齊心協力，確保產品從創新到應用的過程中，兼顧易用性、品質和供應鏈的韌性。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 針對多種被忽視的熱帶疾病，快速擴展的多重即時診斷平台整合了人工智慧主導的影像分析技術，並應用於多種被忽視的熱帶疾病的診斷。
  • 在資源匱乏的環境中，擴大基於 CRISPR 的診斷檢測方法在熱帶疾病病原體超靈敏檢測的應用
  • 利用等溫擴增技術開發攜帶式分子診斷設備，用於被忽視的熱帶感染疾病的現場監測
  • 加強公共衛生機構與生物技術公司之間的夥伴關係，以便在偏遠流行地區部署下一代診斷技術。
  • 利用機器學習技術準確識別寄生蟲種類的智慧型手機顯微鏡應用程式的出現。
  • 利用快速側向層析免疫檢測擴大社區血清學篩檢項目，以早期發現被忽視的熱帶疾病
  • 整合雲端連接診斷終端，用於即時數據收集和被忽視的熱帶疾病流行病學繪圖
  • 用於同時定量分析血清檢體中被忽視的熱帶病生物標記的多重ELISA試劑盒的創新
  • 監管方面的進展為高負擔低收入國家的新型被忽視的熱帶疾病診斷工具提供了快速核准途徑。
  • 擴大行動實驗室網路，為熱帶疾病流行地區的疫情熱點地區提供基於DNA的病原體檢測

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 被忽視的熱帶疾病診斷市場（依技術分類）

  • 免疫檢測
    • 化學冷光檢測法
    • 酵素結合免疫吸附檢測法
  • 顯微鏡
    • 螢光顯微鏡
    • 光學顯微鏡
  • 分子診斷
    • 等溫擴增
    • 聚合酵素鏈鎖反應
  • 快速診斷測試
    • 抗體檢測
    • 抗原檢測

9. 被忽視的熱帶疾病診斷市場（依疾病類型分類）

  • 南美錐蟲病
    • 酵素結合免疫吸附檢測法
    • 聚合酵素鏈鎖反應
  • 利什曼原蟲症
    • 皮膚利什曼原蟲症檢測
    • 利什曼原蟲症檢測
  • 淋巴絲蟲病
    • 抗體檢測
    • 層析法試驗
  • 盤尾絲蟲病
    • 聚合酵素鏈鎖反應
    • 皮膚顯微鏡檢查
  • 血吸蟲病
    • 糞便顯微鏡檢查
    • 尿抗原檢測

第10章 被忽視的熱帶疾病診斷市場（以最終用戶分類）

  • 診所
    • 社區醫療中心
    • 基層醫療診所
  • 診斷實驗室
    • 獨立實驗室
    • 參考實驗室
  • 醫院
    • 私立醫院
    • 公立醫院
  • 研究所

第11章 被忽視的熱帶疾病診斷市場（按應用分類）

  • 確認性檢查
    • 實驗室確診檢測
    • 照護現場確認
  • 篩檢
    • 社區篩檢
    • 大規模藥物管理篩檢
  • 監視
    • 流行病學監測
    • 根除後監測

第12章 被忽視的熱帶疾病診斷市場（依樣本類型分類）

  • 血
    • 血清血漿
    • 全血
  • 航班
    • 濃縮法
    • 直接塗片
  • 組織
    • 切片檢查
    • 皮膚剪
  • 尿
    • 濃縮尿液檢查
    • 直接尿液檢查

13. 被忽視的熱帶疾病診斷市場（按地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 被忽視的熱帶疾病診斷市場（按類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國被忽視的熱帶疾病診斷市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • bioMerieux SA
    • QIAGEN GmbH
    • Becton, Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Hologic, Inc.
    • Coris BioConcept SA
Product Code: MRR-742BD5181EB6

The Neglected Tropical Diseases Diagnosis Market is projected to grow by USD 11.27 billion at a CAGR of 6.04% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 7.04 billion
Estimated Year [2025] USD 7.47 billion
Forecast Year [2032] USD 11.27 billion
CAGR (%) 6.04%

Contextual introduction that situates neglected tropical diseases diagnostics within global health priorities and operational realities to guide strategic decision making

Neglected tropical diseases (NTDs) remain a persistent public health challenge in many low- and middle-income settings, placing complex diagnostic demands on health systems and development partners. Diagnostic strategies for NTDs must reconcile the need for sensitivity and specificity with constraints in infrastructure, workforce capacity, and supply chain resilience. As global health actors pivot toward integrated disease management and elimination goals, diagnostics assume a central role both as enablers of clinical care and as surveillance instruments for programmatic decision-making.

This executive summary synthesizes current diagnostic technology trends, disease-specific testing pathways, end-user dynamics, and regional programmatic drivers that shape the evolving landscape. The intent is to provide healthcare leaders, diagnostic developers, procurement agencies, and policy makers with a concise yet comprehensive analytical foundation to support strategic planning. By framing diagnostic innovation alongside operational realities, the summary highlights where technological advances, policy shifts, and financing mechanisms intersect to accelerate-or in some cases impede-progress against NTDs.

The content emphasizes practical implications for stakeholders who must balance diagnostic performance with affordability, accessibility, and sustainability. It also underscores the interplay between point-of-care approaches and centralized laboratory confirmation, illustrating how diverse testing modalities contribute differently to case detection, surveillance, and program validation across varied epidemiological contexts.

Analysis of the pivotal technological, regulatory, programmatic, and procurement shifts reshaping diagnostics for neglected tropical diseases across diverse health systems

The diagnostic landscape for NTDs is undergoing several transformative shifts driven by converging technological, programmatic, and policy forces. Innovations in molecular biology, miniaturized instrumentation, and digital connectivity have lowered some technical barriers, enabling more sensitive assays to be used in decentralized settings. At the same time, there is an increasing emphasis on integrated diagnostics that support multi-disease screening and surveillance, reflecting a broader push for health system efficiencies and resource optimization.

Regulatory evolution and quality assurance frameworks are also reshaping product pathways. Greater attention to validation in real-world contexts, along with calls for harmonized performance standards, is prompting manufacturers and developers to design assays that meet both laboratory and point-of-care expectations. Procurement behaviors are shifting toward outcome-based and pooled purchasing mechanisms, encouraging suppliers to align product portfolios with programmatic needs rather than purely laboratory-driven specifications.

Operationally, community-level programs are demanding tests that are rapid, robust under field conditions, and deliver clear actionable outputs for frontline workers. Simultaneously, centralized laboratories continue to require high-throughput, confirmatory platforms to validate cases and support elimination verification. These dual imperatives are driving hybrid strategies that pair on-site screening with confirmatory laboratory workflows, supported by digital reporting chains that enable faster public health action and improved surveillance granularity.

Examination of how evolving trade policies and tariff pressures are altering diagnostic sourcing strategies, supply chain resilience, and procurement trade-offs for program sustainability

Recent shifts in trade policy and tariff structures in major markets have introduced new cost considerations into diagnostic supply chains, affecting sourcing strategies for reagents, consumables, and diagnostic hardware. Changes to import duties and customs practices can influence not only landed costs but also the agility of procurement cycles, which are critical when programs require rapid scale-up during outbreak responses or mass drug administration campaigns. The interplay between tariff rules and regional manufacturing capacity has become an important determinant of where suppliers choose to localize production or stock inventory.

For program planners and procurement officers, the practical implication is a reassessment of supplier portfolios and an increased focus on supply chain redundancy. Organizations are evaluating the trade-offs between single-source procurement of validated products and diversified sourcing that mitigates tariff-driven price volatility or border-related delays. In some cases, increased tariffs have accelerated conversations about regional manufacturing partnerships and technology transfer models that can insulate programs from future policy shocks.

Operationally, tariff-induced cost pressures tend to magnify the advantage of diagnostic approaches that minimize recurring imports, such as assays with longer shelf-lives, reduced cold-chain dependence, or platforms compatible with locally produced consumables. As a result, stakeholders are reexamining test selection criteria with supply chain resilience and total cost of ownership in mind, favoring solutions that balance diagnostic performance with pragmatic logistics under evolving trade conditions.

Comprehensive segmentation-driven insights that map diagnostic technologies, disease-specific needs, end-user contexts, applications, and sample types to implementation priorities

A nuanced understanding of segmentation across technology, disease type, end user, application, and sample type reveals distinct pathways for innovation and implementation. In the technology domain, immunoassays-encompassing chemiluminescence assays and enzyme-linked immunosorbent assays-remain important for serological surveillance and confirmatory testing, while microscopy approaches, including fluorescence and light microscopy, continue to serve as low-cost diagnostic backbones in many settings. Molecular diagnostics, represented by polymerase chain reaction and isothermal amplification methods, offer high sensitivity for low-parasite-burden infections and play an increasingly central role in confirmation workflows. Rapid diagnostic tests, with both antigen and antibody detection formats, provide the speed and simplicity required for community screening and point-of-care decision-making.

Disease-specific diagnostics show differentiated needs that shape product development and deployment. Chagas diagnostics frequently pair enzyme-linked immunosorbent assay and polymerase chain reaction to address both chronic serology and acute parasitemia detection, whereas leishmaniasis diagnostics bifurcate into tests optimized for cutaneous and visceral presentations. Lymphatic filariasis relies heavily on antibody detection tests alongside immunochromatographic approaches for mass screening, while onchocerciasis often requires polymerase chain reaction and skin snip microscopy methods depending on program stage. Schistosomiasis testing strategies blend stool microscopy concentration techniques with urine antigen assays to accommodate community-level mapping and individual case confirmation.

End-user contexts strongly influence acceptable product attributes. Clinics and primary care settings prioritize ease of use and minimal infrastructure requirements, community health centers need durable tests suited for outreach, diagnostic laboratories demand standardized protocols and traceability, and hospitals-both private and public-require integration with clinical workflows and laboratory information systems. Research institutes further drive innovation by evaluating novel biomarkers and validation protocols. Applications range from confirmatory laboratory and point-of-care confirmation to community screening approaches that support mass drug administration, and surveillance activities that span epidemiological monitoring through to post-elimination vigilance. Sample type considerations-blood in serum, plasma or whole blood formats, stool through concentration or direct smear, tissue from biopsies or skin snips, and urine via concentrated or direct testing-determine pre-analytical workflows and influence test design choices such as input volumes, preservation requirements, and biosafety implications.

Taken together, segmentation insights highlight where manufacturers can differentiate offerings by aligning technology platforms with disease-specific performance needs, by tailoring workflows to end-user capacity, and by optimizing sample handling to suit programmatic realities. This segmentation-driven lens helps stakeholders prioritize investments that close diagnostic gaps while ensuring practical deployability across diverse operational environments.

Regional programmatic and operational dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine diagnostic access and implementation choices

Regional dynamics continue to shape programmatic priorities, diagnostic accessibility, and product adoption pathways. In the Americas, urban-rural disparities and pockets of endemicity require a blend of laboratory confirmation capacity in tertiary centers and rapid screening tools for remote outreach, with an emphasis on integrating NTD diagnostics into broader primary care services. Cross-border coordination and regional public health initiatives influence procurement harmonization and data sharing practices that support targeted elimination programs.

Europe, Middle East & Africa presents a heterogeneous landscape where some countries possess advanced laboratory infrastructure while others face significant resource constraints. This region's priorities often include strengthening laboratory networks, building quality assurance systems, and enabling decentralized diagnostics that can function with intermittent power and limited cold-chain capacity. Regulatory environments and fragmented procurement mechanisms in parts of the region make harmonized validation and pooled purchasing attractive options for reducing duplicative costs and improving access.

Asia-Pacific exhibits a wide spectrum of epidemiological contexts, from densely populated urban centers to remote island communities. Program strategies here emphasize scalable screening modalities, integration with other endemic disease programs, and investments in local manufacturing capacity to shorten supply chains. The region's growing diagnostic manufacturing footprint and increasing public-private collaboration present opportunities to adapt technologies for both high-volume surveillance and sensitive case confirmation in low-transmission settings.

Insights into the competitive landscape, collaborative partnerships, and product differentiation strategies shaping the neglected tropical diseases diagnostics sector

The competitive ecosystem for NTD diagnostics includes a mix of established diagnostics manufacturers, specialized niche developers, academic laboratories, and contract research organizations that support validation and clinical evaluation. Established firms are adapting portfolios to address the need for integrated testing solutions and digital connectivity, while smaller innovators often focus on disruptive platforms such as simplified isothermal amplification, novel antigen detection chemistries, and instrument-free readouts designed for field deployment.

Collaborations between commercial entities and academic research centers accelerate translation of novel biomarkers into deployable assays, and partnerships with non-governmental organizations and global health donors help pilot products in real-world program settings. Contract development and manufacturing organizations play a critical role in scaling production and ensuring quality systems compliance, particularly for late-stage validation and prequalification. Procurement entities increasingly expect suppliers to demonstrate robust post-market surveillance and support mechanisms for training, quality control, and supply continuity.

For companies seeking to differentiate, investment in usability testing, end-user training materials, and digital integration capabilities can create competitive advantage. Similarly, strategic alliances that enable regional manufacturing or in-country assembly can mitigate supply chain disruption and improve access in markets where localization reduces logistical friction and supports program sustainability.

Actionable recommendations for manufacturers, funders, and program planners to align diagnostic innovation with field deployment realities and program sustainability

Industry leaders should adopt a pragmatic, multi-pronged approach that aligns innovation with implementation realities. First, prioritize development pathways that emphasize robustness, ease of use, and minimal reliance on complex cold chains or sophisticated infrastructure, thereby expanding the range of settings where diagnostics can be effectively deployed. Second, invest in validation studies that demonstrate performance in programmatic conditions and across relevant sample types to build confidence among procurement agencies and frontline providers.

Third, cultivate regional manufacturing or assembly partnerships to reduce exposure to cross-border trade disruptions and to shorten lead times for consumables and instruments. Fourth, design pricing and distribution models that reflect the total cost of ownership, including training, quality assurance, and maintenance, and engage early with procurement stakeholders to align product specifications with program budgets and policy frameworks. Fifth, incorporate digital reporting capabilities that streamline data flows from peripheral testing sites to central surveillance systems, enabling faster public health responses and more efficient program monitoring.

Finally, adopt collaborative commercialization strategies that include partnerships with non-governmental organizations, governmental programs, and research institutes to facilitate field evaluations, user feedback loops, and phased roll-outs that inform product iteration. By executing on these priorities, industry leaders can ensure that investments in technology translate into measurable improvements in case detection, surveillance quality, and programmatic impact.

Clear explanation of the mixed-methods research approach combining stakeholder interviews, literature synthesis, and comparative analysis to underpin the insights presented

This report synthesizes primary and secondary research, combining stakeholder interviews, product performance literature, regulatory guidance documents, and field validation studies to triangulate insights. Primary inputs include structured interviews with diagnostic developers, laboratory directors, clinicians in endemic settings, procurement specialists, and public health program managers, which provided qualitative perspectives on usability, supply chain considerations, and adoption barriers. Secondary sources comprised peer-reviewed literature on diagnostic performance, publicly available regulatory standards, and technical guidance from global health authorities related to NTD program implementation.

Analytical methods included cross-segmentation mapping to identify alignment and gaps between technology attributes and end-user needs, scenario analysis to assess supply chain and procurement sensitivities, and comparative assessment of diagnostic workflows across disease-specific contexts. Where available, real-world validation data and field study outcomes informed assessments of operational suitability. The methodology prioritized transparency by documenting data provenance, interview protocols, and criteria used for technology and product evaluation, enabling reproducibility and informed follow-up research.

Limitations include variability in published performance data across settings and the evolving nature of regulatory pathways, which require ongoing monitoring. Nonetheless, the mixed-methods approach provides a robust foundation for strategic decision-making by combining empirical evidence with practical stakeholder perspectives drawn from diverse geographic and institutional contexts.

Strategic conclusion emphasizing pragmatic innovation, partnerships, and procurement alignment as the pathway to improved diagnostics and durable public health gains

Diagnostics are central to progress against neglected tropical diseases, serving both individual patient care and population-level program objectives. The convergence of technological advances, shifting procurement practices, and heightened emphasis on surveillance creates a window of opportunity to close diagnostic gaps that have persisted for decades. Realizing this potential requires coordinated action across developers, funders, program implementers, and regulatory bodies to ensure that products move from innovation to deployment with attention to usability, quality, and supply chain resilience.

Strategic investments in regionally appropriate technologies, validation in programmatic contexts, and mechanisms that de-risk local manufacturing will accelerate access and sustainability. Moreover, integrated approaches that combine rapid screening at the community level with confirmatory laboratory workflows and strengthened data systems will enhance detection sensitivity while supporting timely public health interventions. The cumulative effect of these steps will be measurable improvements in case finding, surveillance fidelity, and the ability to validate elimination milestones in endemic regions.

Ultimately, the path forward is one of pragmatic innovation: technologies that meet field realities, partnerships that bridge development and delivery, and procurement strategies that emphasize reliability and total cost considerations. Stakeholders who align their initiatives with these principles will be best positioned to translate diagnostic advances into durable public health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid expansion of multiplex point-of-care diagnostic platforms integrating AI-driven image analysis for multiple neglected tropical diseases
  • 5.2. Growing adoption of CRISPR-based diagnostic assays enabling ultra-sensitive detection of tropical disease pathogens in low-resource settings
  • 5.3. Development of portable molecular diagnostic devices leveraging isothermal amplification for field-level surveillance of neglected tropical infections
  • 5.4. Increasing partnerships between public health agencies and biotech firms to deploy next-generation diagnostics in remote endemic regions
  • 5.5. Emergence of smartphone-enabled microscopy apps using machine learning to accurately identify parasite species in point-of-need scenarios
  • 5.6. Scaling up of community-based serological screening programs supported by rapid lateral flow immunoassays for early detection of NTDs
  • 5.7. Integration of cloud-connected diagnostic kiosks for real-time data collection and epidemiological mapping of neglected tropical diseases
  • 5.8. Innovation in multiplex ELISA kits for simultaneous quantification of multiple neglected tropical disease biomarkers in serum samples
  • 5.9. Regulatory advances facilitating accelerated approval pathways for novel NTD diagnostic tools in highly burdened low-income countries
  • 5.10. Expansion of mobile laboratory networks offering DNA-based pathogen detection in outbreak hotspots of tropical disease endemic areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Diseases Diagnosis Market, by Technology

  • 8.1. Immunoassays
    • 8.1.1. Chemiluminescence Assay
    • 8.1.2. Enzyme Linked Immunosorbent Assay
  • 8.2. Microscopy
    • 8.2.1. Fluorescence Microscopy
    • 8.2.2. Light Microscopy
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. Polymerase Chain Reaction
  • 8.4. Rapid Diagnostic Tests
    • 8.4.1. Antibody Detection
    • 8.4.2. Antigen Detection

9. Neglected Tropical Diseases Diagnosis Market, by Disease Type

  • 9.1. Chagas Disease
    • 9.1.1. Enzyme Linked Immunosorbent Assay
    • 9.1.2. Polymerase Chain Reaction
  • 9.2. Leishmaniasis
    • 9.2.1. Cutaneous Leishmaniasis Tests
    • 9.2.2. Visceral Leishmaniasis Tests
  • 9.3. Lymphatic Filariasis
    • 9.3.1. Antibody Detection Test
    • 9.3.2. Immunochromatographic Test
  • 9.4. Onchocerciasis
    • 9.4.1. Polymerase Chain Reaction
    • 9.4.2. Skin Snip Microscopy
  • 9.5. Schistosomiasis
    • 9.5.1. Stool Microscopy
    • 9.5.2. Urine Antigen Test

10. Neglected Tropical Diseases Diagnosis Market, by End User

  • 10.1. Clinics
    • 10.1.1. Community Health Centers
    • 10.1.2. Primary Care Clinics
  • 10.2. Diagnostic Laboratories
    • 10.2.1. Independent Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Hospitals
    • 10.3.1. Private Hospitals
    • 10.3.2. Public Hospitals
  • 10.4. Research Institutes

11. Neglected Tropical Diseases Diagnosis Market, by Application

  • 11.1. Confirmatory Testing
    • 11.1.1. Laboratory Confirmation
    • 11.1.2. Point Of Care Confirmation
  • 11.2. Screening
    • 11.2.1. Community Screening
    • 11.2.2. Mass Drug Administration Screening
  • 11.3. Surveillance
    • 11.3.1. Epidemiological Surveillance
    • 11.3.2. Post Elimination Surveillance

12. Neglected Tropical Diseases Diagnosis Market, by Sample Type

  • 12.1. Blood
    • 12.1.1. Serum Plasma
    • 12.1.2. Whole Blood
  • 12.2. Stool
    • 12.2.1. Concentration Technique
    • 12.2.2. Direct Smear
  • 12.3. Tissue
    • 12.3.1. Biopsy
    • 12.3.2. Skin Snip
  • 12.4. Urine
    • 12.4.1. Concentrated Urine Test
    • 12.4.2. Direct Urine Test

13. Neglected Tropical Diseases Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neglected Tropical Diseases Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neglected Tropical Diseases Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche AG
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Thermo Fisher Scientific Inc.
    • 16.3.4. Danaher Corporation
    • 16.3.5. bioMerieux SA
    • 16.3.6. QIAGEN GmbH
    • 16.3.7. Becton, Dickinson and Company
    • 16.3.8. Bio-Rad Laboratories, Inc.
    • 16.3.9. Hologic, Inc.
    • 16.3.10. Coris BioConcept SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHEMILUMINESCENCE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY FLUORESCENCE MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LIGHT MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RAPID DIAGNOSTIC TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIGEN DETECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CHAGAS DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LEISHMANIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CUTANEOUS LEISHMANIASIS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY VISCERAL LEISHMANIASIS TESTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY LYMPHATIC FILARIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ANTIBODY DETECTION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY IMMUNOCHROMATOGRAPHIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY ONCHOCERCIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SKIN SNIP MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY SCHISTOSOMIASIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY STOOL MICROSCOPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY URINE ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIMARY CARE CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY INDEPENDENT LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CONFIRMATORY TESTING, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL NEGLECTED TROPICAL DISEASES DIAGNOSIS MARKET SIZE, BY CO